C4 Therapeutics, Inc. Stock

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT 5-day change 1st Jan Change
4.24 USD +4.69% Intraday chart for C4 Therapeutics, Inc. -3.20% -24.96%
Sales 2024 * 25.69M 35.13M Sales 2025 * 16.86M 23.07M Capitalization 292M 399M
Net income 2024 * -116M -159M Net income 2025 * -149M -204M EV / Sales 2024 * -0.22 x
Net cash position 2024 * 297M 407M Net cash position 2025 * 286M 391M EV / Sales 2025 * 0.33 x
P/E ratio 2024 *
-2.64 x
P/E ratio 2025 *
-2.22 x
Employees 145
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.26%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.69%
1 week-3.20%
Current month-15.20%
1 month-23.88%
3 months-48.42%
6 months-4.93%
Current year-24.96%
More quotes
1 week
3.91
Extreme 3.91
4.36
1 month
3.91
Extreme 3.91
5.58
Current year
3.91
Extreme 3.91
11.88
1 year
1.06
Extreme 1.06
11.88
3 years
1.06
Extreme 1.06
51.21
5 years
1.06
Extreme 1.06
51.21
10 years
1.06
Extreme 1.06
51.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 20-09-13
Director of Finance/CFO 47 20-11-19
Chief Tech/Sci/R&D Officer - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 76 15-11-30
Corporate Officer/Principal 55 15-11-30
Director/Board Member 67 22-07-28
More insiders
Date Price Change Volume
24-06-21 4.24 +4.69% 8,877,014
24-06-20 4.05 -0.74% 1,558,043
24-06-18 4.08 -1.45% 1,294,348
24-06-17 4.14 -5.48% 1,895,260

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm

More quotes
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.24 USD
Average target price
17.38 USD
Spread / Average Target
+309.79%
Consensus